Healix is a National Provider of Trogarzo™ (ibalizumab-uiyk)
Trogarzo™ is a new humanized monoclonal antibody for the treatment of multidrug-resistant (MDR) HIV-1 infection. This drug has a new mechanism of action and is the first FDA-approved CD-4 detected post-attachment HIV-1 inhibitor.
Trogarzo™ is administered intravenously every 14 days and is used in combination with other antiretroviral drugs.
Consider working with Healix to insource the administration of Trogarzo™ and other therapies for treatment of infections and chronic diseases within your practice.